For research use only. Not for therapeutic Use.
Selexipag-d7 (CAS: 1265295-21-3), a premium pharmaceutical research compound designed for advanced studies in pulmonary arterial hypertension and cardiovascular research. As a deuterated analog of Selexipag, it offers enhanced stability and improved pharmacokinetic properties. Selexipag-d7 is ideal for use in pharmacological and biochemical research, providing precise and reliable data for your studies. This high-purity compound ensures consistent results, aiding in the development of novel therapies for pulmonary arterial hypertension. Trusted by leading laboratories, Selexipag-d7 is your go-to solution for cutting-edge cardiovascular research. Unlock new possibilities in pulmonary hypertension treatment with Selexipag-d7, where innovation meets reliability.
| Catalog Number | S000133 |
| CAS Number | 1265295-21-3 |
| Molecular Formula | C26H25D7N4O4S |
| Purity | ≥95% |
| IUPAC Name | 2-[4-[(5,6-diphenylpyrazin-2-yl)-(1,1,1,2,3,3,3-heptadeuteriopropan-2-yl)amino]butoxy]-N-methylsulfonylacetamide |
| InChI | InChI=1S/C26H32N4O4S/c1-20(2)30(16-10-11-17-34-19-24(31)29-35(3,32)33)23-18-27-25(21-12-6-4-7-13-21)26(28-23)22-14-8-5-9-15-22/h4-9,12-15,18,20H,10-11,16-17,19H2,1-3H3,(H,29,31)/i1D3,2D3,20D |
| InChIKey | QXWZQTURMXZVHJ-ZGBMZCDDSA-N |
| SMILES | [2H]C([2H])([2H])C([2H])(C([2H])([2H])[2H])N(CCCCOCC(=O)NS(=O)(=O)C)C1=CN=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3 |
| Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Kuwano K, et al. 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther. 2007 Sep;322(3):1181-8. [3]. Mous DS, et al. Treatment of rat congenital diaphragmatic hernia with sildenafil and NS-304, selexipag’s active compound, at the pseudoglandular stage improves lung vasculature. Am J Physiol Lung Cell Mol Physiol. 2018 May 10. |
